CYTEK BIOSCIENCES, INC. Business Acquisition, Pro Forma Net Income (Loss)
CYTEK BIOSCIENCES, INC. (CTKB) reported Business Acquisition, Pro Forma Net Income (Loss) of $6.36 million for the 3-month period ending 2023-12-31, per its 10-K filed 2024-03-13.
Discontinued › Expense Statement › Operating Expenses
us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss · last filed 2024-03-13
- CYTEK BIOSCIENCES, INC. business acquisition, pro forma net income (loss) for the quarter ending 2023-12-31 was $6.36M, a 70.98% increase year-over-year.
- CYTEK BIOSCIENCES, INC. business acquisition, pro forma net income (loss) for the quarter ending 2023-09-30 was -$6.46M, a 1459.16% decline year-over-year.
- CYTEK BIOSCIENCES, INC. business acquisition, pro forma net income (loss) for the quarter ending 2023-06-30 was -$4.46M.
- CYTEK BIOSCIENCES, INC. business acquisition, pro forma net income (loss) for the quarter ending 2023-03-31 was -$6.21M.
- CYTEK BIOSCIENCES, INC. business acquisition, pro forma net income (loss) for fiscal 2023 was -$10.81M.
- CYTEK BIOSCIENCES, INC. business acquisition, pro forma net income (loss) for fiscal 2022 was -$753.00K.
| Period end | Business Acquisition, Pro Forma Net Income (Loss) 3 month | Business Acquisition, Pro Forma Net Income (Loss) 6 month | Business Acquisition, Pro Forma Net Income (Loss) 9 month | Business Acquisition, Pro Forma Net Income (Loss) 12 month |
|---|---|---|---|---|
| 2023-12-31 | $6.36M 10-K · filed 2024-03-13 | -$99.00K derived: sum of 2 quarters · filed 2024-03-13 | -$4.55M derived: sum of 3 quarters · filed 2024-03-13 | -$10.81M 10-K · filed 2024-03-13 |
| 2023-09-30 | -$6.46M 10-Q · filed 2023-11-14 | -$10.91M derived: sum of 2 quarters · filed 2023-11-14 | -$17.17M 10-Q · filed 2023-11-14 | -$13.41M derived: sum of 4 quarters · filed 2024-03-13 |
| 2023-06-30 | -$4.46M 10-Q · filed 2023-08-08 | -$10.67M 10-Q · filed 2023-08-08 | -$6.95M derived: sum of 3 quarters · filed 2024-03-13 | -$6.47M derived: sum of 4 quarters · filed 2024-03-13 |
| 2023-03-31 | -$6.21M 10-Q · filed 2023-05-09 | -$2.49M derived: sum of 2 quarters · filed 2024-03-13 | -$2.02M derived: sum of 3 quarters · filed 2024-03-13 | -$3.38M derived: sum of 4 quarters · filed 2024-03-13 |
| 2022-12-31 | $3.72M 10-K · filed 2024-03-13 | $4.19M derived: sum of 2 quarters · filed 2024-03-13 | $2.83M derived: sum of 3 quarters · filed 2024-03-13 | -$753.00K 10-K · filed 2024-03-13 |
| 2022-09-30 | $475.00K 10-Q · filed 2023-11-14 | -$889.00K derived: sum of 2 quarters · filed 2023-11-14 | -$4.47M 10-Q · filed 2023-11-14 | |
| 2022-06-30 | -$1.36M 10-Q · filed 2023-08-08 | -$4.95M 10-Q · filed 2023-08-08 | ||
| 2022-03-31 | -$3.58M 10-Q · filed 2023-05-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (PACB) | United States | $0.491B | -3.95 |
| 908 Devices Inc. (MASS) | United States | $0.476B | -9.53 |
| EyePoint, Inc. (EYPT) | United States | $0.314B | -3.96 |
| Quanterix Corp (QTRX) | United States | $0.150B | -1.65 |
| Nautilus Biotechnology, Inc. (NAUT) | United States | $0.129B | -4.16 |
| Seer, Inc. (SEER) | United States | $0.104B | -1.34 |
| Precipio, Inc. (PRPO) | United States | $0.043B | -36.70 |
| HARVARD BIOSCIENCE INC (HBIO) | United States | $0.037B | -2.70 |
| Bionano Genomics, Inc. (BNGO) | United States | $0.020B | -0.42 |
| ASTROTECH Corp (ASTC) | United States | $0.013B |